KR20220116490A - 공통 리더 서열을 갖는 bcr 트랜스제닉 마우스 - Google Patents

공통 리더 서열을 갖는 bcr 트랜스제닉 마우스 Download PDF

Info

Publication number
KR20220116490A
KR20220116490A KR1020227024093A KR20227024093A KR20220116490A KR 20220116490 A KR20220116490 A KR 20220116490A KR 1020227024093 A KR1020227024093 A KR 1020227024093A KR 20227024093 A KR20227024093 A KR 20227024093A KR 20220116490 A KR20220116490 A KR 20220116490A
Authority
KR
South Korea
Prior art keywords
human
leader
leader peptide
sequence
gene segments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227024093A
Other languages
English (en)
Korean (ko)
Inventor
랠스턴 엠. 반스
아르빈드 라즈팔
아일란 루
가브리엘 우
존 엠. 마제르카크
아나스타샤 프리트버거
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20220116490A publication Critical patent/KR20220116490A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020227024093A 2019-12-18 2020-12-17 공통 리더 서열을 갖는 bcr 트랜스제닉 마우스 Pending KR20220116490A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962949707P 2019-12-18 2019-12-18
US62/949,707 2019-12-18
PCT/US2020/065450 WO2021127068A1 (en) 2019-12-18 2020-12-17 Bcr transgenic mice with a common leader sequence

Publications (1)

Publication Number Publication Date
KR20220116490A true KR20220116490A (ko) 2022-08-23

Family

ID=74106210

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227024093A Pending KR20220116490A (ko) 2019-12-18 2020-12-17 공통 리더 서열을 갖는 bcr 트랜스제닉 마우스

Country Status (6)

Country Link
US (1) US20230071042A1 (enExample)
EP (1) EP4075965A1 (enExample)
JP (1) JP7716406B2 (enExample)
KR (1) KR20220116490A (enExample)
CN (1) CN114867345A (enExample)
WO (1) WO2021127068A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120365434A (zh) * 2024-01-23 2025-07-25 上海苹谱医疗科技有限公司 一种提高凝血因子ⅷ分泌水平的双信号肽及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE158021T1 (de) * 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP4238138B2 (ja) * 2001-12-22 2009-03-11 ４−アンチボディ アーゲー 遺伝的に修飾された脊椎動物前駆体リンパ球の生成方法及び異種結合タンパク質の産生を目的としたその使用。
ES2473596T3 (es) * 2003-07-15 2014-07-07 Therapeutic Human Polyclonals, Inc. Loci de inmunoglobulina humanizada
US20140045472A1 (en) * 2012-08-13 2014-02-13 Qualcomm Incorporated Provisioning-free memberless group communication sessions
RU2019121863A (ru) * 2013-09-18 2019-08-29 Регенерон Фармасьютикалз, Инк. Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения
GB201518792D0 (en) 2015-10-23 2015-12-09 Univ Manchester Production of proteins

Also Published As

Publication number Publication date
CN114867345A (zh) 2022-08-05
JP2023508290A (ja) 2023-03-02
EP4075965A1 (en) 2022-10-26
US20230071042A1 (en) 2023-03-09
JP7716406B2 (ja) 2025-07-31
WO2021127068A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
CN112912397B (zh) 抗cd3抗体及其用途
RU2569157C2 (ru) Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом
JP7178342B2 (ja) アゴニズム及びエフェクター機能が増強した改変抗体、及び他のＦｃドメイン含有分子
US20240383987A1 (en) Antibodies binding to hla-a2/mage-a4
JP2024054340A (ja) 癌の治療に用いるための細胞傷害誘導治療剤
CN104918957B (zh) 抗-cd40抗体及其使用方法
TW202515920A (zh) 具有經受限cd3結合的多重特異性多肽構築體及使用其之方法
TW202039566A (zh) 結合cd3之抗體
KR20260036383A (ko) Cd19에 결합하는 중쇄 항체
US20240042032A1 (en) Anti-cd19 antibodies and car-t structures
JP2009529920A (ja) Ｒａｇｅの拮抗作用のための方法および組成物
KR20240082409A (ko) Cd24를 표적화하는 항체와 이의 제조 및 용도
CN103635488A (zh) 抗-cd40抗体及其使用方法
CN104203981A (zh) 双特异性抗体分子
JP2024513951A (ja) 抗ｃｄ２０抗体及びｃａｒ－ｔ構造
JP2024508808A (ja) 抗ｍｕｃ１－ｃ抗体及びｃａｒ－ｔ構造
US20240018255A1 (en) ANTI-SIRPalpha ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND USE THEREOF
US20250388683A1 (en) Anti-canine interleukine-31-receptor a (il-31ra) antibodies and the use thereof
JP7716406B2 (ja) 共通のリーダー配列を有するｂｃｒトランスジェニックマウス
GB2576914A (en) Antigen-binding molecules comprising unpaired variable domains produced in mammals
WO2023083298A1 (zh) 抗icosl抗体融合蛋白及用途
US20260071002A1 (en) Antibodies binding to ceacam5
EP4512243A1 (en) Binding molecules
EA050049B1 (ru) Антитела к cd19 и car-t-клеточные структуры
WO2025224084A1 (en) Proteins comprising t cell receptor constant domains

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13 Search requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D13-SRH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902